Skip to main content
NMRA
NASDAQ Life Sciences

Neumora Gets Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.367
Mkt Cap
$68.995M
52W Low
$0.315
52W High
$3.65
52W Position info
16% above low
Off High info
90% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NMRA sits 16% above its 52-week low of $0.315.

Summary

Neumora received a Nasdaq notice on October 26, 2026 that its stock has traded below the $1.00 minimum bid and has until April 26, 2027 to regain compliance, with a reverse stock split among the options it is considering.


Key Events · Legal and Risk Events · NMRA

  • Nasdaq Minimum Bid Deficiency Notice

    Nasdaq notified Neumora on October 26, 2026 that it is not in compliance with Listing Rule 5450(a)(1), which requires a $1.00 minimum bid price on the Nasdaq Global Select Market.

  • 180-Day Cure Window to April 2027

    The company has until April 26, 2027 to close at or above $1.00 for a minimum of ten consecutive business days; today's price of $0.3672 is far below that threshold.

  • Reverse Split Flagged as an Option

    Neumora said it will monitor its closing bid price and consider options including a reverse stock split, with no assurance it regains compliance.

  • Capital Market Transfer Fallback

    If it misses the deadline, the company could apply to move to the Nasdaq Capital Market, which requires meeting market value of publicly held shares and other initial listing standards plus an application fee.


Analysis · NMRA · Life Sciences

Neumora's stock closed below $1.00 long enough to trigger a Nasdaq listing-rule notice, and the company now has until April 26, 2027 to hold a $1.00 bid for ten straight business days. That is a steep climb from today's $0.3672, and the company's own suggested fix — a reverse stock split — would shrink the share count without adding a dollar of value. The notice lands on top of a going-concern warning already disclosed in the August 10-Q, so the market is now pricing both a cash runway problem and a listing problem at the same time. Failure to cure leads to a delisting notice, with an appeal that Nasdaq may deny.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NMRA was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69M. The 52-week trading range was $0.32 to $3.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NMRA - Latest Insights

NMRA
Aug 14, 2026, 7:23 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.65
Real-time Price: $0.459 info
Change: -$1.19 (-72%) info
Market Cap: $80.589M info
NMRA
Aug 14, 2026, 7:13 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.459 info
Change: -$1.19 (-72%) info
Market Cap: $80.589M info
NMRA
Aug 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.459 info
Change: -$1.19 (-72%) info
Market Cap: $80.589M info
NMRA
Jul 27, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.459 info
Change: -$1.06 (-70%) info
Market Cap: $80.589M info
NMRA
Jun 16, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.9185
Real-time Price: $0.459 info
Change: -$0.4595 (-50%) info
Market Cap: $80.589M info